弥散加权MRI联合残差卷积神经网络可精准预测世界卫生组织IV级胶质瘤端粒酶逆转录酶启动子突变状态
本研究纳入266例世界卫生组织IV级胶质瘤患者的MRI数据与分子信息,按约10:3分为训练集与验证集,对结构与弥散加权成像分别训练残差卷积神经网络。结构MRI预测端粒酶逆转录酶启动子突变状态效能较差(准确率51%-54%,AUC 0.545-0.571),而弥散加权成像联合表观弥散系数图预测效能最佳(准确率85.2%,AUC 0.934),全肿瘤体积预测效能最佳。
要点
- 弥散加权成像联合表观弥散系数图预测IV级胶质瘤端粒酶逆转录酶启动子突变准确率85.2%、AUC 0.934。
- 结构MRI预测端粒酶逆转录酶启动子突变效能差,准确率51%-54%、AUC 0.545-0.571。
- 全肿瘤体积作为感兴趣区预测端粒酶逆转录酶启动子突变状态效能最佳。
核心结论
- 弥散加权成像技术有望预测世界卫生组织IV级胶质瘤的端粒酶逆转录酶启动子突变,作者认为应将其纳入临床实践中世界卫生组织IV级胶质瘤的MRI方案。
研究设计与样本
- 研究纳入266例世界卫生组织IV级胶质瘤患者的MRI数据与分子信息,按约10:3分为训练集与验证集,对结构MRI(T1加权、T2加权、增强T1加权)与弥散加权成像分别训练相同的残差卷积神经网络,并比较不同感兴趣区对预测结果的影响。
诊断标准与关键数值
- 结构MRI各模态预测端粒酶逆转录酶启动子突变状态准确率51%-54%、AUC 0.545-0.571;弥散加权成像联合表观弥散系数图预测准确率85.2%、AUC 0.934。
临床应用与阅片要点
- 作者认为弥散加权成像技术有望预测世界卫生组织IV级胶质瘤的端粒酶逆转录酶启动子突变,并认为应将其纳入临床实践中世界卫生组织IV级胶质瘤的MRI方案;纳入影像学与临床特征未进一步提升预测效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Telomerase reverse transcriptase promoter (pTERT) mutation status plays a key role in making decisions and predicting prognoses for patients with World Health Organization (WHO) grade IV glioma. This study was conducted to assess the value of diffusion-weighted imaging (DWI) for predicting pTERT mutation status in WHO grade IV glioma.
METHODS: MRI data and molecular information were obtained for 266 patients with WHO grade IV glioma at the hospital and divided into training and validation sets. The ratio of training to validation set was approximately 10:3. We trained the same residual convolutional neural network (ResNet) for each MR modality, including structural MRIs (T1-weighted, T2-weighted, and contrast-enhanced T1-weighted) and DWI*, to compare the predictive capacities between DWI and conventional structural MRI. We also explored the effects of different regions of interest on pTERT mutation status prediction outcomes.
RESULTS: Structural MRI modalities poorly predicted the pTERT mutation status (accuracy = 51%-54%; area under the curve [AUC]=0.545-0.571), whereas DWI combined with its apparent diffusive coefficient maps yielded the best predictive performance (accuracy = 85.2%, AUC = 0.934). Including the radiological and clinical characteristics did not further improve the performance for predicting pTERT mutation status. The entire tumour volume yielded the best prediction performance.
CONCLUSIONS: DWI technology shows promising potential for predicting pTERT mutations in WHO grade IV glioma and should be included in the MRI protocol for WHO grade IV glioma in clinical practice.
ADVANCES IN KNOWLEDGE: This is the first large-scale model study to validate the predictive value of DWI for pTERT in WHO grade IV glioma.
引用
- Hu C, Fang K, Du Q, et al. Diffusion-weighted MRI precisely predicts telomerase reverse transcriptase promoter mutation status in World Health Organization grade IV gliomas using a residual convolutional neural network. Br J Radiol. 2024. PMID: 39152999. doi:10.1093/bjr/tqae146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。